Amicus Therapeutics — Q1 2021 Earnings Presentation
23 slides from Amicus Therapeutics's earnings presentation, May 10, 2021
Slide 1: 1Q21 Financial Results Conference Call & Webcast
1Q21 Financial Results Conference Call & Webcast May 10, 2021
Slide 2: Forward-Looking Statements
Introduction 2 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinica
Slide 3: A leading fully integrated, global rare disease biotechnology company
A leading fully integrated, global rare disease biotechnology company Gene Therapy PLATFORM Protein Engineering & Glycobiology BIOLOGICS Capabilities EMPLOYEES in 27 Countries AT-GAA Phase 3 in Pompe Disease GLOBAL Robust R&D Engine Nearly 50+ Lysosomal Disorders and More Introduction 3 Cash as of 3
Slide 4: 2021 Key Strategic Priorities
Introduction4 2021 Key Strategic Priorities 1Achieve double-digit Galafold growth and revenue of $300M to $315M 2 3 4 5Maintain strong financial position
Slide 5: Galafold Global Launch
Galafold® (migalastat) Global Launch… …taking a leadership role in the treatment of Fabry disease “We push ideas as far and as fast as possible” - Amicus Belief Statement
Slide 6: Galafold: Precision Medicine for Fabry Disease
Galafold is an orally delivered small molecule precision medicine with a unique mechanism of action for Fabry patients with amenable variants that replaces the need for intravenously delivered ERT One of the Most Successful Rare Disease Launches 1,384 Amenable Mutations Included in the EU Label $66.
Slide 7: Galafold Success and FY21 Revenue Guidance
Galafold momentum remains on track to achieve full year 2021 revenue guidance FY21 Rev. Guidance $300M-$315M $260.9M $182.2M $91.2M $5.0M Q1 $66.4M Galafold: Precision Medicine for Fabry Disease 7 Galafold Success and FY21 Revenue Guidance FY16FY17FY18FY19FY20FY21
Slide 8: Continued double-digit Galafold revenue growth to $300M-$315M in 2021
Galafold: Precision Medicine for Fabry Disease8 Continued double-digit Galafold revenue growth to $300M-$315M in 2021 Galafold Continues Strong Launch Performance & Cornerstone of Amicus Success Global demand remains strong with continued growth anticipated in 2021 and beyond Number of patients on G
Slide 9: Galafold Opportunity
With inherent Fabry market growth and our work to improve screening and diagnosis, Galafold has the potential to drive $1B+ annual revenue at peak ~$500M Projected Revenue $1B+ Opportunity Peak $91M 2018 1st year of launch in major geographies $261M 2020 Continued momentum across geographies 2023 Dr
Slide 10: AT-GAA: Next Potential Standard of Care for Pompe Disease
AT-GAA: Next Potential Standard of Care for Pompe Disease “We encourage and embrace constant innovation” - Amicus Belief Statement
Slide 11: Pompe Disease Overview
11 Pompe Disease Overview Pompe disease is a severe and fatal neuromuscular disease and one of the most prevalent lysosomal disorders with very high unmet medical need AT-GAA for Pompe Disease Deficiency of GAA leading to glycogen accumulation and cellular dysfunction Age of onset ranges from infanc
Slide 12: PROPEL Study Endpoint Heat Map
AT-GAA for Pompe Disease 12 Phase 3 PROPEL Study Primary, Key Secondary and Biomarker Endpoint Heat Map Endpoints across motor function, pulmonary function, muscle strength, PROs and biomarkers favored AT-GAA over alglucosidase alfa in both the overall and ERT experienced populations Note: * Nominal
Slide 13: AT-GAA: Next Steps
13 AT-GAA: Next Steps AT-GAA for Pompe Disease AT-GAA for Pompe Advances Toward Approval Rolling BLA submission expected to complete in 2Q Other key regulatory submissions for approval throughout 2021 including MAA in Europe Potential for early approval under EAMS framework with Priority Innovative
Slide 14: Next Generation Gene Therapy Platform
Next Generation Gene Therapy Platform “We have a duty to obsolete our own technologies” - Amicus Belief Statement
Slide 15: Next Generation Gene Therapy Platform pipeline
Fabry Franchise Galafold®(migalastat) Monotherapy DISCOVERYPRECLINICALPHASE 1/2PHASE 3REGULATORYCOMMERCIAL ODD Pompe Franchise AT-GAA (Novel ERT + Enzyme Stabilizer) ODD BTD Pompe Gene TherapyPENN Batten Franchise – Gene Therapies CLN6 Batten Disease CLN3 Batten Disease ODD ODD RPD RPD PRIME NCH NCH
Slide 16: Amicus Protein Engineering Expertise Technologies for Gene Therapy
16 Amicus Protein Engineering Expertise Technologies for Gene Therapy Next Generation Gene Therapy Platform Differentiated gene therapy approach for greater potency and optimized cross correction through transgene engineering for stability and targeting Proprietary AAV capsid Pantropic capsid and ub
Slide 17: Financial Summary
Financial Summary “We are business led and science driven” - Amicus Belief Statement
Slide 18: 1Q2021 Select Financial Results
Financial Summary 18 1Q2021 Select Financial Results 1Q2021 revenue of $66.4M primarily from global Galafold sales Mar. 31, 2021 Mar. 31, 2020 Product Revenue $66,402 $60,525 Cost of Goods Sold 6,539 6,552 R&D Expense 64,117 89,120 SG&A Expense 46,726 40,215 Changes in Fair Value of Contingent Consi
Slide 19: Financial Outlook: Key Takeaways
19 Financial Outlook: Key Takeaways Reaffirming full-year Galafold revenue guidance of $300 million to $315 million Non-GAAP operating expense guidance for 2021 is expected to remain flat at $410 million to $420 million - Driven by disciplined expense management and continued investment in the globa
Slide 20: Closing Remarks
Closing Remarks "We believe in our future to build long-term value for our stakeholders" - Amicus Belief Statement
Slide 21: Thank You
Thank You “Our passion for making a difference unites us” -Amicus Belief Statement
Slide 22: Appendix
Appendix Amicus Therapeutics
Slide 23: Reconciliation of Non-GAAP Financial Measures
Appendix Reconciliation Amicus Therapeutics, Inc. Reconciliation of Non-GAAP Financial Measures (in thousands) Three Months Ended March 31, 2021 2020 Total operating expenses - as reported GAAP S 112,918 S$ 132,030 Research and development: Share-based compensation 6,305 5,253 Selling, general and a